Introduction
The cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a homologous molecule of CD28 that plays a critical role in the control of T-cell activation. CTLA-4 has greater affinity and avidity for B7 than does CD28, and its translocation to the cell surface after T-cell activation results in a negative signal, which is responsible for T-cell inactivation. [1] [2] [3] The human CTLA-4 gene is located on 2q33, in a susceptibility region for autoimmune diseases. Several single-nucleotide polymorphisms have been described within the CTLA-4 gene. Among these single-nucleotide polymorphisms, the most studied have been þ 49A/G in exon 1, which leads to an alanine-to-threonine amino-acid substitution at codon 17 in the leader peptide, and CT60, located in the 3 0 -untranslated region of the gene. The G allele of þ 49A/G and the CT60 G allele have been reported to increase susceptibility to several autoimmune diseases 4, 5 but it has also been related to a decrease in graft-versus-host disease after allogeneic transplantation. 6 Moreover, certain CTLA-4 polymorphisms have been reported to be more prevalent in patients with renal cancer or sporadic breast cancer, 7 suggesting that increased expression of CTLA-4 would be associated with a decreased ability of the immune system to detect and eliminate tumor-associated antigens. However, little is known about the relationship between the CTLA-4 genotype and the incidence of cancer relapse once complete remission has been obtained through chemotherapy.
Although acute myeloid leukemia (AML) can be cured after standard chemotherapy and stem cell transplantation (SCT), relapse after the first complete remission remains one of the main causes of mortality. Here, we attempt to determine whether the CTLA-4 gene polymorphism CT60 influences the clinical outcome of patients with AML after obtaining the first complete remission through standard induction chemotherapy.
Patients and methods

Patients
Participants included in this analysis were 198 adult patients younger than 60 years. They all had primary AML and were enrolled and treated in 19 Spanish institutions involved in the prospective LAM'03 trial of the 'Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias' (CETLAM). This study was opened for accrual in August 2003 and is still recruiting patients. The corresponding institutional review boards approved the study and all patients signed an informed consent form before entering the study. Inclusion criteria were as follows: age between 18 and 60 years, diagnosis of AML according to the French-American-British classification, no history of myelodysplasia or previous cytotoxic drugs or radiation and absence of severe concomitant disease. Patients with acute promyelocytic leukemia were excluded and treated in a separate trial.
In /12 h intravenously (days 1, 3, 5); patients with normal cytogenetics (in 20 metaphases), without MLL rearrangement, FLT3-ITD negative and requiring only one course of induction chemotherapy to achieve complete remission were assigned to receive an autologous peripheral blood transplantation as the post-remission strategy. The remaining patients (that is, patients with cytogenetic abnormalities other than t(8;21) or inv(16), FLT3-ITD positive, those without valuable mitoses or those with normal karyotype requiring two cycles to achieve complete remission) were allocated to allogenic SCT or autologous transplantation according to human leukocyte antigen-identical sibling donor availability.
Complete remission was defined as the presence of less than 5% of blast cells in a bone marrow smear after the first or second course of induction therapy. Patients with a reduction of less than 50% in marrow leukemia cells after the first course and those who did not achieve a complete remission after two courses were considered as refractory and were excluded.
CTLA-4 genotyping
DNA was obtained from peripheral blood or bone marrow samples by standard procedures. PCR-restriction fragment length polymorphism (PCR-RFLP) was used to genotype the CTLA-4 CT60 single-nucleotide polymorphism. The primers used were: forward 5 0 -CACCACTATTTGGGATATACC-3 0 , reverse 5 0 -AGCTCTATATTTCAGGAAGGC-3 0 . PCRs were performed with 100 ng DNA, as previously described, 6 and 3 ml of the amplified products were digested for 1 h at 37 1C with 1 U of NcoI (New England Biolabs, Beverly, MA, USA) in a total reaction volume of 10 ml. The digestion products were resolved in 3% agarose gels stained with ethidium bromide. Patients were stratified into two groups according to their CT60 genotype: patients homozygous for the CT60 A allele and patients carrying at least one G allele (AG or GG).
Statistical analysis
Homogeneity between the CT60 AA and the CT60 AG/GG cohorts was calculated using the w 2 -test for qualitative variables and the Student's t-test for continuous variables. Overall survival (OS) and disease-free survival (DFS) were calculated by means of the Kaplan-Meier method with comparison of curves using the log-rank test. Statistical incidence estimates were used to determine the cumulative incidence of relapse and non-relapse mortality depending on the CT60 genotype. Death in complete remission was considered a competing risk in the analysis of relapse incidence. For non-relapse mortality, relapse was the competing risk.
Multivariate Cox regression models using a forward stepwise procedure with the likelihood ratio criterion (inclusion/ exclusion criteria: Pp0.05/P40.10, respectively) were applied to analyze the combined effects of CTLA-4 CT60 polymorphism and other factors on OS and relapse. All variables in the univariate analysis with a P-value at or below 0.2 were included in the multivariate analysis.
Results
CT60 genotype distribution
After receiving standard induction chemotherapy, 143 out of 198 patients obtained complete remission (72.2%). Twenty-six patients (13.1%) showed chemoresistance and 25 (12.6%) died due to complications during the treatment. Four cases could not be evaluated for remission. When considering only those patients achieving complete remission, we were able to obtain the CT60 genotype in 138 cases: 39 patients (28.2%) were homozygous for the CT60 A allele, whereas 99 (71.8%) were carriers of at least one G allele (CT60 AG/GG). These genotype frequencies were similar in the patients who did not enter remission and are comparable to those previously described in healthy stem cell donors. Table 1 shows the comparison of these two groups as regards the clinical characteristics of the patients. No significant differences were detected with respect to age, French-American-British subtype, cytogenetics according to the Medical Research Council criteria or FLT3 internal tandem duplication (FLT3-ITD), number of cycles needed to obtain complete remission or type of stem cell transplant received.
Overall survival
An increased OS at 3 years was observed for patients with the CT60 AG/GG genotype when compared with the cohort of patients homozygous for the CT60 A allele (68.4 vs 39.4%; P ¼ 0.013) (Figure 1 ). This association was maintained in the Table 2 shows the results of the multivariate analysis.
We also analyzed the impact of the CTLA-4 CT60 genotype on OS considering only those patients with intermediate-risk cytogenetics according to the Medical Research Council criteria, which represented the majority of patients (n ¼ 89). This analysis revealed the same differences when considering the whole series (CT60 AG/GG: 68.1% vs CT60 AA: 28.2%; P ¼ 0.005).
When considering the type of SCT, we found that patients receiving an autologous transplant also had a better OS at 3 years when the CTLA-4 CT60 genotype was AG/GG (83.3 vs 53.4%; P ¼ 0.048). This effect was not observed after allogeneic transplant.
Relapse
We observed that patients with a CT60 AA genotype relapsed more frequently than those with a CT60 AG/GG genotype (56.4 vs 35.6%; P ¼ 0.003) (Figure 2 ). Multivariate analysis showed that the CT60 AA genotype was an independent risk factor for relapse (P ¼ 0.004; HR ¼ 2.64, 95% CI ¼ 1.36-5.14). Table 2 also shows the multivariate analysis for relapse.
Patients receiving an autologous transplant also had a higher relapse incidence when the CTLA-4 CT60 genotype was AA; however, this difference did not reach statistical significance, probably due to the limited number of cases (AA: 59.1% vs AG/GG: 33.2%; P ¼ 0.070).
Disease-free survival
As expected given the increased risk of relapse and worse OS, DFS was affected by the CTLA-4 CT60 genotype. Patients with the CT60 AA genotype had worse DFS than those with at least one G allele (32.3 vs 53.9%; P ¼ 0.004) (Figure 3) .
Regarding those patients who received an autologous SCT, the difference in DFS was similar, without reaching statistical significance (39.2 vs 64.9%; P ¼ 0.065). We found no differences in non-relapse mortality with respect to the CTLA-4 CT60 genotype (CT60 AA: 5.8% vs CT60 AG/GG: 11.7%, P ¼ 0.393).
Discussion
CTLA-4 is a key factor in regulating and maintaining selftolerance, providing a negative signal to the T cell and thus limiting immune responses. Several polymorphisms within the CTLA4 gene have been associated with an increased risk of developing autoimmune diseases. The most widely studied of these polymorphisms have been þ 49 A/G, CT60, À318 C/T and À1722 C/T. 8, 9 Specifically, the presence of a G allele in the þ 49 position or in the CT60 single-nucleotide polymorphism in the 3 0 -untranslated region has been identified as a risk factor for developing coeliac disease, systemic lupus erythematosus, multiple sclerosis, chronic inflammatory arthropathies, Sjö gren's syndrome or autoimmune thyroiditis.
10-12
Figure 2 Relapse incidence after obtaining first complete remission with standard induction chemotherapy, depending on the CTLA-4 CT60 genotype. CTLA-4 genotype and AML relapse A Pérez-García et al Moreover, a high incidence of CTLA-4 CT60 AA and þ 49 AA genotypes has been reported in patients with renal cell cancer, suggesting a role for the CTLA4 gene in tumor development. 13 In other words, the presence of a more tolerogenic CTLA4 genotype could represent a potential form of tumor immune evasion. However, little is known regarding the impact of the CTLA-4 genotype on the maintenance of cancer remission once the treatment with chemotherapy has been successful.
The role of immunological surveillance as a mechanism to control minimal residual disease is controversial in patients with AML, because induction chemotherapy may impair the ability of T lymphocytes to recognize tumor-associated antigens. Moreover, the previously described low level of expression of costimulatory molecules on the surface of leukemic blasts may also facilitate tumor escape from immune system action. 14 However, it has been reported that vaccination strategies using leukemia-associated antigens, such as WT1 or PR1, may be associated with the development of specific autologous cytotoxic T cells and with clinical responses, suggesting that the autologous immune response is important in the control of leukemic proliferation. 15 We found that AML patients with the CTLA4 CT60 AA genotype have a higher relapse incidence after obtaining a first complete remission with standard chemotherapy, leading to worse OS. It therefore seems possible that the presence of a 'tolerogenic' CTLA4 genotype is associated with a lower ability of the immune system to detect and eliminate residual leukemic cells.
The CT60 AA genotype has been reported to increase the production of the soluble form of CTLA4, and we have previously described an increased risk of graft-versus-host disease and lower relapse rate after allogeneic SCT when the donor's CTLA4 CT60 genotype was homozygous for the A allele. 6 These previous results seem to contradict not only those of this study but also the more frequent observation of the CT60 G genotype in patients with autoimmune diseases. However, it should be considered that, in the context of an allogeneic SCT, T lymphocytes from the donor may recognize a broad spectrum of minor histocompatibility antigens, enhancing the occurrence of immune reactions. Moreover, it has been recently reported that the soluble form of CTLA4 (sCTLA4) is able to suppress proliferation of autoreactive T-cell clones, whereas abatacept (CTLA4-Ig) and belatacept (LEA29Y) are not. In contrast, CTLA4Ig and LEA29Y, as opposed to sCTLA4, are able to suppress naive alloreactive proliferation in a mixed leukocyte reaction, indicating a differential role for sCTLA4, CTLA4Ig and LEA29Y proteins in memory versus primary immune responses. 16 The observation that immune inhibitory pathways through CTLA-4 may influence leukemic relapse after obtaining complete remission with standard chemotherapy is relevant because the blockade of these inhibitory signals appears to be a promising strategy for leukemia immunotherapy. Following this rationale, two different fully-human anti-CTLA-4 antibodies (ipilimumab and tremelimumab) have shown promising antitumour activity in patients with advanced melanoma. 17 According to our results, it would seem appropriate to test the usefulness of these antibodies in maintaining AML complete remission, at least in patients with high-risk leukemia and the CTLA-4 CT60 AA genotype.
Conclusion
We conclude that CTLA-4 polymorphisms are involved in the incidence of AML relapse after obtaining first complete remission through standard chemotherapy, thus suggesting the ability of the immune system to control minimal residual disease.
